Angiotensin-receptor blockers (ARBs), a class of medications used by millions worldwide to treat hypertension, may be linked to cancer, a study published today in Lancet Oncology claims. In an analysis of 60,000 patients, researchers found a 1 percent higher risk of getting cancer in people who took the drug compared to those who did not.
Angiotensin-receptor blockers (ARBs), a class of medications used by millions worldwide to treat hypertension, may be linked to cancer, a study published today in Lancet Oncology claims. In an analysis of 60,000 patients, researchers found a 1 percent higher risk of getting cancer in people who took the drug compared to those who did not.